Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 3.2% - What's Next?

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report) shares fell 3.2% during trading on Wednesday . The stock traded as low as $2.23 and last traded at $2.26. 635,514 shares changed hands during trading, a decline of 59% from the average session volume of 1,549,982 shares. The stock had previously closed at $2.33.

Analysts Set New Price Targets

Several brokerages have commented on AUTL. Wells Fargo & Company lowered their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a research report on Friday, March 21st. Needham & Company LLC restated a "buy" rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Thursday. Finally, Truist Financial lowered their price objective on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Price Performance

The firm's fifty day moving average price is $1.55 and its 200-day moving average price is $1.95. The company has a market capitalization of $564.22 million, a price-to-earnings ratio of -1.75 and a beta of 1.76.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $8.98 million for the quarter, compared to the consensus estimate of $1.59 million. On average, research analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new stake in Autolus Therapeutics in the fourth quarter valued at $26,000. Barclays PLC raised its position in Autolus Therapeutics by 1,094.3% during the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after purchasing an additional 10,866 shares during the last quarter. Invesco Ltd. raised its position in Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after purchasing an additional 11,381 shares during the last quarter. Daiwa Securities Group Inc. raised its position in Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after purchasing an additional 8,479 shares during the last quarter. Finally, Virtus ETF Advisers LLC raised its position in Autolus Therapeutics by 29.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after purchasing an additional 6,081 shares during the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.